Retatrutide, GLP-1s and the Gallbladder: What the Trials Counted

What the gallbladder does

Picture a small squeeze bottle tucked under your liver. That is your gallbladder. It is about the size of a small pear.

Your liver makes bile all day. Bile breaks up fat so your gut can take it in. Between meals, the bile sits in the bottle and waits.

Then you eat something with fat in it. Your gut sends out a signal. The bottle squeezes. Bile shoots down a tube into your small intestine. Job done.

That squeeze matters more than it sounds. Bile is not simple liquid. It carries cholesterol, salts and other bits. If it sits still too long, those bits start to clump.

Clumps become sludge. Sludge becomes stones.

So the whole story comes down to one thing: does the bottle keep getting squeezed?

Hold that picture. The rest of this page is about the things that stop the squeeze.

Three things push the same way

Someone loses a lot of weight on one of these drugs. Three things happen at once. All three push toward stones.

One: the squeeze gets weaker

Your gut releases a signal called CCK when fat arrives. CCK is what tells the bottle to squeeze.

These drugs lower that signal. A 2025 review in Therapeutic Advances in Endocrinology and Metabolism walked through the biology. Less CCK means a weaker, slower squeeze. The timing can go off too. Then the bottle empties in an uneven way.

Bile sits longer. That is the first push.

Two: the bile itself changes

The same review describes a second problem. These drugs shift how bile salts get recycled. Two switches in that system, called FXR and TGR5, get less signal than usual.

The result is bile that carries more cholesterol than it can hold.

Think of stirring too much sugar into a cup of tea. Past a point it stops dissolving and sinks to the bottom. Bile does the same thing with cholesterol.

Three: losing fat dumps cholesterol into bile

This one has nothing to do with drugs. When body fat breaks down fast, a lot of cholesterol moves through the liver. The liver pushes it into bile.

So the bile gets thicker at the exact moment the bottle is squeezing less.

That is the whole problem in one sentence. Thicker liquid, weaker squeeze, same bag.

What the trials counted

This is not a theory. It has been counted, more than once.

The big pooled look

In March 2022, JAMA Internal Medicine published a study that pooled 76 proper trials. That covered 103,371 people. Average age 57.8. Average BMI 32.6.

Here is what it found.

Now the part that matters most here. The study split the trials by why the drug was given.

Read those last four rows again. Low dose, short course: nothing. High dose, long course, for weight loss: more than double.

That pattern tells you something. The risk is not really about the drug being present. It tracks with how much weight comes off and how fast.

The semaglutide numbers

A 2026 pooled look in Diabetes, Obesity and Metabolism took the STEP trials apart. Four trials. 3,683 people. 2,269 on semaglutide 2.4mg, 1,414 on placebo.

Gallbladder events: 59 people on the drug, 16 on placebo. That is 2.6% against 1.1%.

The authors put it in plain terms. About one extra gallbladder event per 90 to 100 people, per year.

Most of those events were plain gallstones. Inflamed gallbladders and surgery were rare.

The approved label for that drug lists its own figures. Gallstones in 1.6% of people on the drug against 0.7% on placebo. Inflamed gallbladder in 0.6% against 0.2%.

So: a real signal, and a small one.

Where retatrutide sits

Retatrutide is a weight-loss compound still in trials. It hits three receptors at once. Most others in this family hit one or two.

Its phase 2 trial was published in the New England Journal of Medicine in 2023. It ran on 338 adults.

That trial did record gallbladder events. Three of them: one inflamed gallbladder and two cases of stones.

Three events in 338 people over less than a year. Take that for what it is worth, which is not much either way. A trial that size cannot measure a risk this small. It was never built to.

Here is the number that matters.

TRIUMPH-4 reported in December 2025. It ran on 445 people. Average starting weight was 112.7 kg. The 12mg group lost 28.7% of their body weight. That is about 32 kg.

Now go back to the pooled study. The gallbladder risk rose most with higher doses, longer courses and weight-loss use. It more than doubled in the weight-loss trials.

Retatrutide takes off more weight than the rest measured in this family. So on the pattern we can see, it sits at the far end of every line.

Nobody has measured it directly yet. That is an honest gap, not a reassurance. The detailed TRIUMPH-4 safety tables have not been published in full. When they are, this section will need rewriting.

Speed is the part people miss

Blame usually lands on the drug. The bigger driver is often how fast the weight comes off.

A Swedish study followed two matched groups through a paid weight-loss plan. 3,320 people in each. It ran a year, across 28 centres.

One group did a very low calorie diet. The other did a plain low calorie diet. No weight-loss drugs in either.

Look at the gap in weight. It is 3 kg over a whole year. That is all.

Three extra kilos, and the risk of a painful stone went up 3.4 times. No drug in it.

Now think about what 28.7% in 68 weeks means next to that. The Swedish group lost about 11 kg. A person on 12mg in TRIUMPH-4 lost about 32 kg.

That is the real frame for this whole topic. These compounds do not have a special grudge against gallbladders. They cause fast, big weight loss. Fast, big weight loss is hard on a gallbladder.

If you have no gallbladder

This is the question that sends most people to this page. It also gets answered wrong more than the rest here.

A common belief is that no gallbladder means you cannot use these compounds.

That is backwards.

Look at the approved label for the closest drug in this family. It lists exactly two hard bars. A personal or family history of a certain thyroid cancer, or a related genetic condition. And a past serious allergic reaction to the drug.

That is the whole list. Gallbladder disease is not on it.

Gallbladder problems appear further down, under warnings. A warning means watch for it. A bar means do not use it at all. They are not the same thing and the label keeps them apart on purpose.

The review goes further. It says these drugs can be started again once the gallbladder is taken out.

That makes sense when you go back to the squeeze bottle. If the bottle is gone, no stone can form in it. Bile drips straight from the liver into the gut instead of being stored.

So there is one group who cannot get gallbladder stones. The group with no gallbladder.

Two honest caveats. Stones can still form in the tubes that carry bile. That is much less common. And some people handle fat in a new way after the surgery. A big change in eating can feel rough for a while.

None of that makes it a bar. It just means the picture is not blank.

If you already have stones

The other half of the question is the half that holds up better.

Stones already sitting in a gallbladder is a different case. Add fast weight loss to a bag that already holds stones. That is the setup for pain.

Here is why. Most stones sit there quietly for years. Trouble starts when one moves and blocks the exit. A bag that suddenly starts acting in a new way is a bag more likely to shift one.

The review names new gallstones as one reason these drugs get stopped.

Note the wording though. Stopped when stones show up. Not banned from the start.

Any decision like this belongs with a doctor who can see the person. A website should not decide it for you. This one is not trying to.

What trials on stopping stones tested

Here is where nearly every page on this topic stops short. Most say “talk to your doctor” and leave it there.

There is actual trial data on preventing stones during weight loss. It is worth knowing it exists.

A 2015 study pooled 13 proper trials. That covered 1,836 people losing weight. Eight trials through dieting, five through weight-loss surgery. It ran in Clinical Gastroenterology and Hepatology.

Two things came out of it.

A bile acid drug

A doctor-only drug called ursodiol cut new stones sharply. Its longer name is ursodeoxycholic acid.

Nine people treated, one stone case stopped. That means for every 9 people given it, one stone case was prevented.

Fat in the diet

The second finding surprises people. Diets with more fat produced fewer stones than low fat diets. In that comparison new stones dropped by 91%.

That sounds wrong until you go back to the bottle. Fat is what triggers the squeeze. Cut fat to almost nothing and the bottle barely empties at all.

So a very low fat crash diet is close to the worst case. Fast weight loss thickening the bile, and almost nothing telling the bag to empty.

What trouble looks like

A stone that sits still causes nothing. Many people carry them for years and never know.

The classic attack has a shape to it. Pain in the upper right of the belly, under the ribs. It often comes on after a meal. It can spread to the right shoulder or the back between the shoulder blades.

It builds, holds steady for a while, then eases. It is not a stabbing that comes and goes in seconds.

Some signs mean it has gone past a plain stone. Fever. Yellow skin or eyes. Pain that will not let up. Not being able to keep food down.

Here is the practical trap. Feeling sick and throwing up are the top side effects of every drug here. So a person on one of these compounds already expects to feel rough.

So it is easy to file a real problem under “the usual.” The pain is what tells them apart. Feeling sick alone is common. Feeling sick with steady pain under the right ribs is not.

This section describes what the medical literature reports. It is not a diagnosis tool. Belly pain that will not settle is a doctor visit, not a web search.

What goes wrong in this area

Most of the noise on this topic falls into a few buckets.

Treating a warning like a ban

People read “gallbladder disease” on a drug label and assume it is a bar. Labels keep bars and warnings apart on purpose. Most pages repeating this have never opened the label.

Quoting one drug’s numbers for another

You will see semaglutide gallbladder percentages used for retatrutide. They are different compounds at different doses producing different amounts of weight loss. Borrowing numbers across them is not evidence.

Blaming the drug for the weight loss

The Swedish diet study had no drug in it. It still showed 3.4 times the risk. Some pages talk about the drug and never mention the speed. That is half the story.

Selling a fix

There is a whole market of “gallbladder support” products aimed at people on weight-loss drugs. None of them have trial data behind them for this. Two things have real trial data. A doctor-only drug, and how much fat is in the diet.

Pretending the gap is filled

We do not know retatrutide’s gallbladder rate at phase 3 doses. Anyone who tells you otherwise has made it up. That gap is the honest answer right now.

What to check before you buy

This part is about the material itself, not the biology.

A test sheet you can check

Ask for the lab report for the lot you are getting. Not a sample report. Not a report with no date. The batch number on the vial should match the batch number on the sheet.

Better still, it should link to the testing lab’s own page. Then you can check the lab really issued it. A PDF from the seller proves nothing.

Purity and what else is in there

A good sheet shows more than one number. Purity is the headline. Mass checks matter too. They confirm the compound is what the label says, not something of a similar weight.

Storage and shipping

These are freeze-dried powders. They are stable dry and much less stable once mixed. Ask how it ships and how it is stored before it ships. In a Canadian summer, a package sitting in a hot vehicle is a real thing.

Claims that should stop you

Some sellers tell you what a compound will do in a person. Or what dose to use. They have stepped outside what this stuff is. These are research chemicals. A seller who forgets that is a seller cutting corners somewhere else too.

Retatrutide$79.99 CADTirzepatide$54 CADRetatrutide 10-Pack$500 CADBacteriostatic Water$10 CADPfizer Bac Water 30ml$24 CADResearch Pen Add-On$99 CAD

Common questions

Bottom line

The useful things here are a pooled study from 2022. A diet study from Sweden. And a 2015 look at stopping stones. The newest compound is the part still being worked out.

Other guides on this site

Sources